Regulatory questions get expensive when they are answered late. A company raises against one plan, builds against another, and discovers the gap in front of a regulator. This work runs the pathway question first, maps what each route demands in evidence, time, and capital, and pressure-tests the plan while it is still cheap to change. It is strategy support and preparation. It is not legal advice, and no regulatory outcome is promised.
This advisory does not obtain, promise, or accelerate any clearance, approval, designation, or coverage decision. It does not make any claim about the safety or effectiveness of any product. Regulatory outcomes rest with the agency.
Founders and leadership teams in biotech, biologics, diagnostics, and medical devices. Healthcare operators whose service model depends on how a rule is read. Boards and investors who need the regulatory assumptions in a plan tested by someone who has lived on the operating side of them.
The perspective comes from three decades building and running FDA-regulated healthcare companies, not from the outside looking in.
A written read of the realistic regulatory routes, the evidence each demands, and the consequences of each for time and capital.
Adversarial review of an existing clinical, operational, or compliance plan, with the gaps and the fixes written down.
Working sessions to get the leadership team ready to engage with FDA and CMS, alongside the company's regulatory counsel and consultants.
I help you make regulatory decisions that do not blow up your business later. My focus is healthcare, biotech, and other complex, regulated environments. I work with founders, operators, and investors to turn vague rules and shifting guidance into a clear, practical plan you can execute.
In regulatory strategy engagements, I start with your business objective. I look at what you are trying to bring to market or grow and where the biggest regulatory pressure sits. Then we map the real options in front of you, the risks tied to each, and what those choices mean for approvals, inspections, post-market obligations, and future expansions.
You get a clear pathway, not a pile of jargon. We define milestones, data needs, operational changes, and decision points. We line that up with FDA, CMS, and other oversight expectations. We also talk through the business impact of each move so you are not compliant on paper but broken in practice.
My job is to help you see the trade-offs before regulators or payers force them on you. That includes work on hospital operations, clinical services, diagnostics, and frontier biotech, where rules are evolving and the cost of guessing wrong is high. I bring three decades of FDA regulated healthcare experience and investor perspective to this, so you get guidance that respects both the law and the numbers.
If you bring me into a regulatory strategy conversation, expect direct questions, clear options, and a documented plan you can show your board, your investors, and your counsel. You do not need perfection. You need informed decisions you do not regret twelve months later.
New clients start with a short, paid Diagnostic Advisory Engagement. Your regulatory position gets examined alongside growth and capital, because they move together.
The Diagnostic Advisory Engagement